A Regina mother who was one of the first ALS patients to test a new treatment is now celebrating its accelerated approval in ...
The decision on the SOD1 ALS program does not impact Voyager’s other gene therapy programs; the Company continues to expect IND filings in 2025 from Neurocrine Biosciences for the program in ...
Nevertheless, the new disappointment with DNL343 is another major disappointment to ALS patients, who have limited drug ...
The decision on the SOD1 ALS program does not impact Voyager’s other gene therapy programs; the Company continues to expect IND filings in 2025 from Neurocrine Biosciences for the program in ...
Health regulators in Canada gave conditionally approval to Qalsody to treat adults whose ALS is due to mutations in the SOD1 ...
Company to assess alternate payloads; no changes planned to novel capsid component - - Resulting shift of timeline and costs ...